WE START THE CONVERSATIONS THAT MATTER
SO OUR CLIENTS CAN CHANGE THE WORLD.

Public and investor relations for the innovators in healthcare and technology
CASE STUDY Launching Super Bowl Campaign for Innovative Knee Cartilage Therapy

Leveraging the Sports-Health Alliance

  • Solomon Wilcots, alongside two NFL orthopedic surgeons, recorded on the virtual Radio Row of Superbowl LV
  • Within one week, the segment was broadcast on targeted state TV stations and national radio programs
  • The media campaign increased web traffic by 109% and drove patients to seek treatment
READ MORE
CASE STUDY Building Social Media from the Ground Up

COVID-19 Vaccine Company Gets the Word Out

  • Conducting a social media assessment to understand the landscape
  • Taking over channels on Twitter, LinkedIn with a monthly plan to position Vaxxinity as a leader
  • Over six months, Twitter followers grew 1,688% and LinkedIn grew 418%
READ MORE
CASE STUDY Harnessing the Power of PR to Attract New Investors​

Generating Awareness to Support the Company

  • Partnering with corporate leadership to create clinical updates
  • Leveraging media connections to prominently feature the client
READ MORE

Explore

Since our founding in 1988, Russo Partners has been working side by side with innovators and influencers in the healthcare and technology industries. Our evolution in the biopharma and healthcare technology ecosystem is unparalleled as is our network, and the knowledge we bring to our clients is extensive. We bring passion, a culture of excellence, forward thinking and client focus every day to everything we do.

Ver­tex adds a new gene edit­ing part­ner, pay­ing Ob­sid­i­an $75M cash for con­trol­lable CRISPR sys­tem
| Endpoints News

When Paul Wotton became CEO of Obsidian Therapeutics two years ago, he asked his team to explore where they could apply the company’s technology beyond cancer. Launched by Michael Gilman in 2017, the GV-backed company had been working on a way of controlling cell therapies after they’re administered to a patient, allowing doctors to modulate […]

read more
Tonix hopes for COVID-19 drug tonic as it pens OyaGen antiviral pact
| Fierce Biotech

Tonix Pharmaceuticals is opening an early-stage antiviral asset deal with OyaGen as the pair targets COVID-19. The research and license pact, financials of which were not made public, focuses on the antiviral inhibitor of SARS-CoV-2, TNX-3500 (aka sangivamycin, formerly OYA1), which Tonix believes can hit back against the pandemic virus and “potentially other viral disorders.” […]

read more